Investitionsthese
Backing exceptional science with disciplined VC capital to build and scale European biopharma companies with real impact, focusing on robust preclinical validation and translational strategies.
Investitionsphase
Early-stage to clinical-stage
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Science-driven innovations addressing unmet medical needs in biopharma
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
k.A.
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (8)
C
Cees Stouten
Senior Drug Development & Manufacturing Expert
F
Frans van Dalen
Founding Partner
F
Frans van Dalen, Pharm.D.
Founding Partner
G
Gerjan Kemperman
Advisory Council Member
P
Paul Lelieveld
Co-Founder
P
Paul Lelieveld, Ir., MSc.
Founding Partner
P
Peter Goedings
Senior Clinical Expert
P
Ping Cao
Advisory Council Member
